First Time Loading...

ADC Therapeutics SA
NYSE:ADCT

Watchlist Manager
ADC Therapeutics SA Logo
ADC Therapeutics SA
NYSE:ADCT
Watchlist
Price: 4.44 USD -7.11%
Updated: Apr 26, 2024

Operating Margin
ADC Therapeutics SA

-238.6%
Current
-851%
Average
-8.3%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-238.6%
=
Operating Profit
-166m
/
Revenue
69.6m

Operating Margin Across Competitors

Operating Margin Comparison
ADC Therapeutics SA Competitors

Country Company Market Cap Operating
Margin
CH
ADC Therapeutics SA
NYSE:ADCT
365.4m USD
-239%
US
Abbvie Inc
NYSE:ABBV
295.4B USD
30%
US
Amgen Inc
NASDAQ:AMGN
144.2B USD
29%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.5B USD
39%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
97.4B USD
32%
AU
CSL Ltd
ASX:CSL
132B AUD
26%
US
Gilead Sciences Inc
NASDAQ:GILD
81.3B USD
34%
US
Seagen Inc
NASDAQ:SGEN
43.1B USD
-33%
US
Moderna Inc
NASDAQ:MRNA
40.6B USD
-62%
US
Biogen Inc
NASDAQ:BIIB
29.3B USD
21%
KR
Celltrion Inc
KRX:068270
36.9T KRW
30%
ADC Therapeutics SA
NYSE:ADCT
Country CH
Market Cap 365.4m USD
Operating Margin
-239%
Abbvie Inc
NYSE:ABBV
Country US
Market Cap 295.4B USD
Operating Margin
30%
Amgen Inc
NASDAQ:AMGN
Country US
Market Cap 144.2B USD
Operating Margin
29%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Country US
Market Cap 102.5B USD
Operating Margin
39%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Country US
Market Cap 97.4B USD
Operating Margin
32%
CSL Ltd
ASX:CSL
Country AU
Market Cap 132B AUD
Operating Margin
26%
Gilead Sciences Inc
NASDAQ:GILD
Country US
Market Cap 81.3B USD
Operating Margin
34%
Seagen Inc
NASDAQ:SGEN
Country US
Market Cap 43.1B USD
Operating Margin
-33%
Moderna Inc
NASDAQ:MRNA
Country US
Market Cap 40.6B USD
Operating Margin
-62%
Biogen Inc
NASDAQ:BIIB
Country US
Market Cap 29.3B USD
Operating Margin
21%
Celltrion Inc
KRX:068270
Country KR
Market Cap 36.9T KRW
Operating Margin
30%

Profitability Report

View the profitability report to see the full profitability analysis for ADC Therapeutics SA.

Full Profitability Report

See Also

Summary
ADCT intrinsic value, competitors valuation, and company profile.
DCF Valuation
ADCT stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ADCT stock valuation using valuation multiples.
Wall Street Estimates
ADCT price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ADCT stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-238.6%
=
Operating Profit
-166m
/
Revenue
69.6m
What is the Operating Margin of ADC Therapeutics SA?

Based on ADC Therapeutics SA's most recent financial statements, the company has Operating Margin of -238.6%.

ALPHA SPREAD
Join more than 131,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.